Reviewed Mar 2026 | PubMed sources
Active Market
This comparison can feed directly into US-first legal, provider, and cost workflows.

Tirzepatide vs Survodutide: Head-to-Head Comparison

Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss. Survodutide is an investigational dual GLP-1/glucagon agonist showing up to 19% weight loss with particular promise for liver fat reduction (MASH). Both are dual agonists but target different receptor combinations.

Approved Comparison Routing

Approved options in this comparison

A
Tirzepatide

Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Tirzepatide with a provider?

Tirzepatide is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Find a provider

Tirzepatide Next Steps

US-first money path

Side-by-Side Comparison

DimensionTirzepatideSurvodutide
Evidence LevelLevel A — Phase 3 RCTs completed and approvedLevel B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA StatusApproved for T2D (Mounjaro) and obesity (Zepbound)Not approved; in Phase 3 trials
Weight Loss EfficacyUp to 22.5% (SURMOUNT-1)Up to 19% (Phase 2 at 46 weeks)
MechanismDual agonist: GIP + GLP-1 receptorsDual agonist: GLP-1 + glucagon receptors
Liver Fat / MASH BenefitSome liver fat reduction observedSignificant liver fat reduction; MASH trials underway
AvailabilityAvailable by prescription nowNot yet available; still in clinical trials
Evidence Level
Tirzepatide
Level A — Phase 3 RCTs completed and approved
Survodutide
Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA Status
Tirzepatide
Approved for T2D (Mounjaro) and obesity (Zepbound)
Survodutide
Not approved; in Phase 3 trials
Weight Loss Efficacy
Tirzepatide
Up to 22.5% (SURMOUNT-1)
Survodutide
Up to 19% (Phase 2 at 46 weeks)
Mechanism
Tirzepatide
Dual agonist: GIP + GLP-1 receptors
Survodutide
Dual agonist: GLP-1 + glucagon receptors
Liver Fat / MASH Benefit
Tirzepatide
Some liver fat reduction observed
Survodutide
Significant liver fat reduction; MASH trials underway
Availability
Tirzepatide
Available by prescription now
Survodutide
Not yet available; still in clinical trials

Peptide Overviews

Tirzepatide

AFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Weight LossFDA Approved
View full Tirzepatide profile →

Survodutide

BHuman Studies

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).

Weight LossNot Approved
View full Survodutide profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Tirzepatide vs Survodutide: FAQ